News Search Results
May 14, 2026, 09:00 ET A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Avaí Bio's Cell-Based Platform Approach
Avaí Bio, Inc. (OTCQB: AVAI) — formerly known as Avant Technologies Inc. — is an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging.[2] The Company has two development
More news about: Equity Insider
May 14, 2026, 09:00 ET OnCusp Therapeutics Appoints Anthony Kim as Chief Financial Officer
appointment of Anthony Kim as Chief Financial Officer. Mr. Kim is a seasoned finance executive with more than 25 years of experience spanning biotechnology leadership and global capital markets. He brings deep expertise in capital formation, investor relations, and corporate strategy, having worked
More news about: OnCusp Therapeutics
May 14, 2026, 09:00 ET Yuyu Pharma's Mervyn's Petcare Launches Cat Dental Care Treat on Amazon, Marking First Overseas Pet Health Push
supplements that improve quality of life. As part of its global growth strategy, the company invests in early-stage and high-growth innovators across biotechnology, sustainability, and animal health through Yuyu Venture Studio.
More news about: Yuyu Pharmaceutical
May 14, 2026, 09:00 ET Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
Catalysts Shaping the Biotech and Pharmaceutical Sectors Include:Artiva Biotherapeutics, Inc. (NASDAQ: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, recently
More news about: Market News Updates
May 14, 2026, 08:56 ET China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit
More news about: China Pharma Holdings, Inc.
May 14, 2026, 08:38 ET Woods Rogers Launches in the Northern Virginia Market with Three Experienced Attorneys
SylviaMary joins Woods Rogers' Litigation & Dispute Resolution Practice Group and Intellectual Property Team. She counsels clients on biotechnology and pharmaceutical patent law, bringing over three decades of combined scientific and legal experience to her practice. Trained as a molecular virologist,
More news about: Woods Rogers
May 14, 2026, 08:30 ET Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis
Therapeutics targeting initiation of first-in-human clinical studies in 2027.About Maipl TherapeuticsMaipl Therapeutics is a biotechnology company focused on repurposing established targets and developing novel therapies for chronic inflammatory conditions. By leveraging deep biological
More news about: Maipl Therapeutics, Inc.
May 14, 2026, 08:10 ET CREATE Medicines Strengthens Clinical and Scientific Advisory Board with Appointment of Georg Schett, MD, Margrit Wiesendanger, MD, PhD, and Christopher Jewell, PhD
CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ -- CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune programming, today announced the expansion of its Clinical and Scientific Advisory Board (SAB) with the appointment
More news about: CREATE Medicines, Inc.
May 14, 2026, 08:05 ET Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Calif., May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company
More news about: Rigel Pharmaceuticals, Inc.
May 14, 2026, 08:00 ET Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates
More news about: Intensity Therapeutics Inc.
May 14, 2026, 08:00 ET CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology
CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ -- CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune programming, today announced the closing of its $122 million Series B funding round, co-led by existing investors
More news about: CREATE Medicines, Inc.
May 14, 2026, 08:00 ET Origin Agritech to Hold Business Update & First Half Fiscal Year 2026 Earnings Conference Call on May 22 at 8 a.m. ET
first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and pest resistance (Bt) traits. For further information, please visit the Company's
More news about: Origin Agritech Limited
May 14, 2026, 07:19 ET Resurge Therapeutics Announces Positive Clinical Results from Two Studies of Its Intraprostatic Drug Elution Platform for Benign Prostatic Hyperplasia (BPH) at AUA 2026
stakeholders to support its next phase of development.About Resurge TherapeuticsResurge Therapeutics is a privately held biotechnology company developing novel localized drug delivery therapies for urological diseases. The company was co-founded by Mikael Trollsas Ph.D., John Stankus
More news about: Resurge Therapeutics
May 14, 2026, 07:10 ET REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
of the webcast will be available for approximately 30 days following the presentation.ABOUT REGENXBIO Inc. REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
May 14, 2026, 07:05 ET Cypherpunk Technologies Reports First Quarter 2026 Financial Results
and foreign tax purposes; and (j) the ability to comply with the continued listing requirements of the Nasdaq Capital Market. With respect to our biotechnology operations, important factors that could cause actual results to differ materially from our plans, estimates or expectations could include, but
More news about: Cypherpunk Technologies Inc.
May 14, 2026, 07:05 ET Cypherpunk Technologies Reports First Quarter 2026 Financial Results
and foreign tax purposes; and (j) the ability to comply with the continued listing requirements of the Nasdaq Capital Market. With respect to our biotechnology operations, important factors that could cause actual results to differ materially from our plans, estimates or expectations could include, but
More news about: Cypherpunk Technologies Inc.
May 14, 2026, 07:00 ET Lilly and UNICEF collaborate to give millions of children a healthier start
pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 14, 2026, 07:00 ET REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
independence, required support for breathing, cardiomyopathy and premature death.About REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered
More news about: REGENXBIO Inc.
May 14, 2026, 03:05 ET Macao Sustainability Leader Sustaincia Joins the Sands Cares Accelerator
inspiration, connection, coordination and verification of sustainable efforts. Sustaincia also organizes events on green mobility and energy transitions, biotechnology exchange, global trends in technology and future career paths for young people. To explore our projects and join our mission, please visit the Community
More news about: Las Vegas Sands Corp.
May 14, 2026, 01:03 ET EBT Medical and NinaMED Announce US$13.75M Financing to Advance Licensed NiNA System® for Overactive Bladder
multiple stages and sectors through strategy-specific funds. SV invests across stages, geographic regions and sectors, with expertise spanning biotechnology, dementia, medical devices and services, and a proven track record of building world-class healthcare companies. For more information, visit:
More news about: NinaMED Pty Ltd
May 14, 2026, 01:00 ET National Kidney Foundation Innovation Fund Invests in Biohope to Advance Personalized Medicine in Kidney Transplantation
May 14, 2026 /PRNewswire/ -- The National Kidney Foundation (NKF) announced today that its Innovation Fund has invested in Biohope, a biotechnology company developing precision diagnostics designed to personalize immunosuppressive therapy for kidney transplant recipients and autoimmune and inflammatory
More news about: National Kidney Foundation
May 13, 2026, 22:09 ET METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, "The SpaceX of Pharmaceuticals" Ushers in a New Era of Biopharmaceuticals
real-world data feedback." To date, METiS TechBio has more than 30 pharmaceutical and biotechnology partners worldwide, with customers primarily including global top-tier pharmaceutical companies, innovative biotechnology companies, and medical research institutions.METiS TechBio recorded revenue
More news about: METiS TechBio
May 13, 2026, 20:15 ET PharmaResearch schließt westeuropäische Roadshow für REJURAN in fünf Märkten ab
weltweit erste injizierbare Produkt für funktionelle und ästhetische Gynäkologie. VIVACY ist vor Kurzem strategische Partnerschaften mit Burgeon Biotechnology für den CaHA-Biostimulator NOVUMA® sowie mit PharmaResearch für den exklusiven europäischen Vertrieb des Skin Boosters REJURAN® auf PN-Basis eingegangen.
More news about: PharmaResearch Co., Ltd.
May 13, 2026, 19:43 ET PharmaResearch achève la tournée de présentation de REJURAN dans cinq marchés d'Europe de l'Ouest
produit injectable au monde pour la gynécologie fonctionnelle et esthétique. VIVACY a récemment conclu des partenariats stratégiques avec Burgeon Biotechnology pour le biostimulateur NOVUMA® CaHA et avec PharmaResearch pour la distribution européenne exclusive du booster de peau REJURAN® PN. Avec des produits
More news about: PharmaResearch Co., Ltd.
May 13, 2026, 19:41 ET PharmaResearch concluye la gira de presentación de REJURAN por cinco mercados de Europa Occidental
el primer inyectable del mundo para la ginecología funcional y estética. VIVACY ha establecido recientemente alianzas estratégicas con Burgeon Biotechnology para el bioestimulador NOVUMA® CaHA, y con PharmaResearch para la distribución exclusiva en Europa del potenciador cutáneo REJURAN® a base de PN.
More news about: PharmaResearch Co., Ltd.